Cancer and neoplasms
New Protocol Title: A Phase 1/2, First-in-Human Study of theMenin-KMT2A (MLL1)Inhibitor Bleximenib in Participants with Acute Leukemia
Previous study title: A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants with Acute Leukemia
This is a first-in-human (FIH), open-label, non-randomised, multicentre, Phase 1 study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of JNJ-75276617 (the study medication) in adult participants with relapsed or refractory acute leukaemia harbouring KMT2A or NPM1 gene alterations.
Leukaemia (cancer of the white blood cells) is diagnosed as acute leukaemia when it progresses quickly and aggressively, and usually requires immediate treatment. Acute leukaemia is classified according to the type of white blood cells affected: Acute ...
GO TO STUDY